Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.
2.

[Synergistic effect and its possible mechanisms of lidamycin in combination with TRAIL in NSCLC].

Yang J, Chen SZ.

Yao Xue Xue Bao. 2010 Oct;45(10):1247-53. Chinese.

PMID:
21348302
3.

TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.

Zhu K, Fang W, Chen Y, Lin S, Chen X.

Oncol Rep. 2014 Sep;32(3):1234-42. doi: 10.3892/or.2014.3324. Epub 2014 Jul 11.

PMID:
25017445
5.

MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.

Azijli K, Yuvaraj S, van Roosmalen I, Flach K, Giovannetti E, Peters GJ, de Jong S, Kruyt FA.

Apoptosis. 2013 Jul;18(7):851-60. doi: 10.1007/s10495-013-0829-3.

PMID:
23456625
6.

The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.

Azijli K, van Roosmalen IA, Smit J, Pillai S, Fukushima M, de Jong S, Peters GJ, Bijnsdorp IV, Kruyt FA.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1273-83. doi: 10.1007/s00280-014-2465-1. Epub 2014 Apr 18.

PMID:
24744163
7.

Effect of Embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAIL-resistant A549 non-small cell lung cancer cells.

Jiang L, Hao JL, Jin ML, Zhang YG, Wei P.

Asian Pac J Cancer Prev. 2013;14(10):6115-20.

8.
9.

Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way.

Xie J, Liu JH, Liu H, Liao XZ, Chen Y, Lin MG, Gu YY, Liu TL, Wang DM, Ge H, Mo SL.

BMC Cancer. 2016 Nov 18;16(1):899.

11.

Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.

Guo L, Fan L, Ren J, Pang Z, Ren Y, Li J, Wen Z, Qian Y, Zhang L, Ma H, Jiang X.

Int J Nanomedicine. 2012;7:1449-60. doi: 10.2147/IJN.S24711. Epub 2012 Mar 19.

13.

5-allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells.

Xie ZH, Quan MF, Liu F, Cao JG, Zhang JS.

BMC Cancer. 2011 Jul 29;11:322. doi: 10.1186/1471-2407-11-322.

14.

[Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].

Li ZW, Yang ZL, Feng HL, Bian XC, Liu YY, Liu YQ.

Zhonghua Bing Li Xue Za Zhi. 2013 May;42(5):330-5. doi: 10.3760/cma.j.issn.0529-5807.2013.05.009. Chinese.

PMID:
24004591
15.

Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.

Gatti L, Cossa G, Tinelli S, Carenini N, Arrighetti N, Pennati M, Cominetti D, De Cesare M, Zunino F, Zaffaroni N, Perego P.

J Pharmacol Exp Ther. 2014 Mar;348(3):360-71. doi: 10.1124/jpet.113.210054. Epub 2013 Dec 17.

16.
17.

Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.

Liu X, Yue P, Zhou Z, Khuri FR, Sun SY.

J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80.

PMID:
15572759
18.

Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.

Kong M, Fan J, Dong A, Cheng H, Xu R.

Acta Biochim Biophys Sin (Shanghai). 2010 Nov;42(11):827-33. doi: 10.1093/abbs/gmq091.

PMID:
20978038
19.

Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.

Li H, Zhu X, Zhang Y, Xiang J, Chen H.

J Exp Clin Cancer Res. 2009 Aug 8;28:110. doi: 10.1186/1756-9966-28-110.

20.

Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells.

Cho Y, Park MJ, Park M, Min SS, Yee J, Kim C, Han MS, Han SH.

Respirology. 2009 Aug;14(6):850-8. doi: 10.1111/j.1440-1843.2009.01563.x.

PMID:
19703066

Supplemental Content

Support Center